PT - JOURNAL ARTICLE AU - Bilinski, Alyssa AU - Mostashari, Farzad AU - Salomon, Joshua A TI - Contact tracing strategies for COVID-19 containment with attenuated physical distancing AID - 10.1101/2020.05.05.20091280 DP - 2020 Jan 01 TA - medRxiv PG - 2020.05.05.20091280 4099 - http://medrxiv.org/content/early/2020/05/20/2020.05.05.20091280.short 4100 - http://medrxiv.org/content/early/2020/05/20/2020.05.05.20091280.full AB - Contact tracing has been recommended as a critical component of containment strategies for COVID-19. We used a simple epidemic model to evaluate how contact tracing might enable modification of current physical distancing restrictions. Testing and tracing coverage need to exceed 50% to see substantial gains; if both are below 50%, contact tracing does not reduce transmission by more than 10%. With 90% testing and tracing as well as high isolation and quarantine efficacy, contact tracing could reduce overall transmission by >45%, which would allow for partial loosening of physical distancing measures. Benefits of contact tracing could be enhanced by testing all contacts rather than only those with symptoms and by policies to support high adherence to voluntary isolation and quarantine.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding sourcesAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNo data used